Shocking!
Risk for cardiogenic shock is elevated in patients having an MI affecting this area of the heart
Left ventricle
This lab test, part of a cardiac biomarker panel, is considered the "gold standard" in diagnosing myocardial infarction
Troponin
This drug is used to reduce platelet aggregation in patients having a myocardial infarction
Aspirin
Differentiates unstable angina from a non-ST elevation myocardial infarction (NSTEMI)
Reversal agent for heparin
Protamine sulfate
With changes occuring at the cellular level, clinical manifestations in this stage of shock are minimal
The early stage
This test provides information on the heart's response to activity
Stress test
This class of drug is used to increase mean arterial pressure for patients in cardiogenic shock
vasopressors (vasoconstrictors)
Coronary vessel referred to as "the widowmaker"
Left anterior descending
Form of chest pain that improves with activity
Prinzmetal's angina (variant)
This hemodynamic parameter is a better indication of perfusion than blood pressure or heart rate
Mean arterial pressure
This diagnostic can determine the patency of the coronary arteries and location of occlusion(s) if present
Angiogram
This drug inhibits the hepatic synthesis of vitamin-K dependent clotting factors
warfarin
Treatment for acute coronary syndrome if no access to facilities with PCI or cardiac surgery
Thrombolytic
Physiologic concept referring to the volume of blood in the ventricle at end-diastole
Preload
This stage of shock is characterized by significantly altered level of consciousness, oliguria, and weak/absent peripheral pulses
Progressive
This diagnostic is a graphic representation of the electrical activity of the heart and can be used to identify myocardial ischemia or necrosis
electrocardiogram (ECG)
Beta blockers
This ECG change is associated with total occlusion of a coronary artery.
ST elevation
Anatomic location of the apex of the heart
4-5th intercostal space left mid-clavicular line
The term used to describe preferential blood flow to essential organs when cardiac output is impaired
shunting
One of two inflammatory markers associated with increased risk of acute coronary syndrome
C-reactive protein
homocysteine
The term to describe drugs that increase force of myocardial muscle contraction
Positive inotrope
ACE inhibitors reduce the production of this hormone, resulting in less fluid retention
Aldosterone
Abnormal muscle catabolism caused by HMG-CoA reductase inhibitors
rhabdomyolysis
Will also accept "rhabdo"